Although its in vitro affinity for TTR T4-binding sites is significantly lower than that of tafamidis, a randomized clinical trial has shown that the diflunisal treatment of patients with FAP for 2 years reduced the rate of progression of neurological impairment35, demonstrating the validity of drug repurposing for TTR amyloidoses. Here, FAP is linked to amyloidosis.